ALSO READJeevan Scientific gets DCGI nod for its Hyderabad centre Kalpataru Power shares up 3 pc on Rs 1,200 cr orders win Laurus Lab debuts at Rs 490 on BSE, up 14.5% over issue price Blockbuster listing for BSE; shares end nearly 33% higher GMR Infrastructure shares rise on buzz over airport business
Dr Reddy's Laboratories today said it has launched a generic version of Sofosbuvir 400 mg and Velpatasvir 100 mg fixed-dose combination, indicated for the treatment of chronic hepatitis C, in the country.
The Hyderabad-based firm has launched its generic product under the brand name Resof Total, Dr Reddy's Laboratories said in a statement.
Dr Reddy's product is a generic version of Gilead's brand Epclusa.
"Treatment with this combination achieves a cure rate of more than 90 per cent in all genotypes of Hepatitis C virus," the company said.
Shares of the company ended 3.54 per cent up at Rs 2,676.15 on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)